Literature DB >> 2253091

Production and characterization of monoclonal antibodies specific for human mast cell tryptase.

A F Walls1, A R Bennett, H M McBride, M J Glennie, S T Holgate, M K Church.   

Abstract

Human mast cell tryptase was purified from lung tissue by high salt extraction, ammonium sulphate precipitation, octyl Sepharose and heparin-agarose chromatography. The tryptase isolated was a tetramer with a molecular weight of 132 kD on gel filtration, and on SDS-polyacrylamide gel electrophoresis was reduced to a single diffuse band with a mean molecular weight of 32.5 kD. Purified tryptase catalysed the cleavage of the tryptic substrates tosyl L-arginine methyl ester and benzoyl DL-arginine p-nitroanilide; enzymatic activity was enhanced in the presence of heparin but markedly decreased in the presence of 2 M sodium chloride. Rabbit antisera and three new monoclonal antibodies (AA1, AA3 and AA5) were produced which were specific for tryptase in indirect ELISAs, immunoenzymatic overlay in crossed immunoelectrophoresis and by Western blotting. Additive and competitive ELISA experiments suggested that the three monoclonal antibodies all recognized epitopes within a single highly immunogenic area of the tryptase molecule, and enzyme assays indicated that this site was distant from the active site. Binding of monoclonal antibodies to tryptase was not affected by the presence of heparin, or by periodate treatment of the antigen suggesting that carbohydrate epitopes were not recognized. Western blotting indicated that some heterogeneity in molecular weight for monomeric tryptase was not reflected in antigenic differences. An immunofluorescence procedure with cytocentrifuge preparations of enzymatically dispersed lung, colon and skin revealed highly specific localization of tryptase to the granules of all mast cells, but there was no binding to other cells in these preparations, to cultured keratinocytes, to basophils or to any other blood leucocyte.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253091     DOI: 10.1111/j.1365-2222.1990.tb03153.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  8 in total

1.  Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease.

Authors:  P Goldsmith; B McGarity; A F Walls; M K Church; G H Millward-Sadler; D A Robertson
Journal:  Dig Dis Sci       Date:  1990-11       Impact factor: 3.199

2.  Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts.

Authors:  J A Cairns; A F Walls
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

3.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

4.  Glycosylation and the activation of proteinase-activated receptor 2 (PAR(2)) by human mast cell tryptase.

Authors:  S J Compton; B Renaux; S J Wijesuriya; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

5.  Tryptase and IgE concentrations in the respiratory tract of infants with acute bronchiolitis.

Authors:  M L Everard; G Fox; A F Walls; D Quint; R Fifield; C Walters; A Swarbrick; A D Milner
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

6.  Vitamin D deficiency leads to sensory and sympathetic denervation of the rat synovium.

Authors:  S E Tague; P G Smith
Journal:  Neuroscience       Date:  2014-09-02       Impact factor: 3.590

7.  Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease.

Authors:  Michael J Hurley; Pascal F Durrenberger; Steve M Gentleman; Andrew F Walls; David T Dexter
Journal:  J Mol Neurosci       Date:  2015-05-17       Impact factor: 3.444

8.  Indoleamine 2,3-dioxygenase (IDO)-1 and IDO-2 activity and severe course of COVID-19.

Authors:  Lihui Guo; Bernadette Schurink; Eva Roos; Esther J Nossent; Jan Willem Duitman; Alexander Pj Vlaar; Paul van der Valk; Frédéric M Vaz; Syun-Ru Yeh; Zachary Geeraerts; Annemiek Dijkhuis; Lonneke van Vught; Marianna Bugiani; René Lutter
Journal:  J Pathol       Date:  2022-01-10       Impact factor: 9.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.